Client News

​Roquefort Therapeutics (LSE:ROQ,OTCQB:ROQAF), the Main Market listed biotech company focused on early-stage opportunities in the biotechnology sector, is pleased to announce that, further to the conditional share sale and purchase agreement (the “Acquisition Agreement”) with the shareholders of Oncogeni Limited (the “Sellers”) as announced on 22 June 2022, the Company has today received approval from the FCA of its prospectus (the “Prospectus”) and published its Prospectus in relation to the proposed acquisition of the entire issued share capital of Oncogeni Limited (“Oncogeni”), the conditional placing for new Ordinary Shares to raise gross proceeds of £1,015,000 (the “Placing”) and the issue of Consideration Shares (as described below).

https://www.londonstockexchange.com/news-article/ROQ/publication-of-prospectus/15627041